This report provides comprehensive insights about XOLAIR for Chronic Spontaneous Urticaria (CSU) in the seven major markets. A detailed picture of the XOLAIR for CSU in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the XOLAIR for CSU.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XOLAIR market forecast analysis for CSU in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in CSU.
XOLAIR is approved for treating CSU in over 80 countries, including the EU, and CIU, as it is known in the US. Additionally, XOLAIR has been approved for allergic asthma, chronic urticaria, and nasal polyps. It is also being investigated in other indications including nasal polyps and food hypersensitivity.
Dosage: 150 mg or 300 mg of XOLAIR is administered by SC injection every 4 weeks to treat CIU. The dosing of XOLAIR in CIU patients is not dependent on serum IgE (free or total) level or body weight. XOLAIR injection is clear to a slightly opalescent and colorless-to-pale brownish-yellow solution available as 150 mg/mL in a single-dose prefilled syringe with a purple needle shield for CSU.
Administration: XOLAIR is available as a prefilled syringe and as a lyophilized powder in a vial for reconstitution. Both XOLAIR prefilled syringes and lyophilized powder should be administered by a healthcare professional. XOLAIR is administered by SC injection, which may take 5-10 s to administer. Also, more than one injection per site should not be administered.
This product will be delivered within 2 business days.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XOLAIR market forecast analysis for CSU in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in CSU.
Drug Summary
XOLAIR (omalizumab) is a recombinant DNA-derived humanized IgG1κ monoclonal antibody that selectively binds to human IgE. The antibody has a molecular weight of approximately 149 kDa, and is approved for the treatment of CSU in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment.XOLAIR is approved for treating CSU in over 80 countries, including the EU, and CIU, as it is known in the US. Additionally, XOLAIR has been approved for allergic asthma, chronic urticaria, and nasal polyps. It is also being investigated in other indications including nasal polyps and food hypersensitivity.
Dosage: 150 mg or 300 mg of XOLAIR is administered by SC injection every 4 weeks to treat CIU. The dosing of XOLAIR in CIU patients is not dependent on serum IgE (free or total) level or body weight. XOLAIR injection is clear to a slightly opalescent and colorless-to-pale brownish-yellow solution available as 150 mg/mL in a single-dose prefilled syringe with a purple needle shield for CSU.
Administration: XOLAIR is available as a prefilled syringe and as a lyophilized powder in a vial for reconstitution. Both XOLAIR prefilled syringes and lyophilized powder should be administered by a healthcare professional. XOLAIR is administered by SC injection, which may take 5-10 s to administer. Also, more than one injection per site should not be administered.
Scope of the Report
The report provides insights into:
- A comprehensive product overview including the XOLAIR description, mechanism of action, dosage and administration, research and development activities in Chronic Spontaneous Urticaria (CSU).
- Elaborated details on XOLAIR regulatory milestones and other development activities have been provided in this report.
- The report also highlights the XOLAIR research and development activities in CSU across the United States, Europe, and Japan.
- The report also covers the patents information with expiry timeline around XOLAIR.
- The report contains forecasted sales of XOLAIR for CSU till 2032.
- Comprehensive coverage of the late-stage emerging therapies for CSU.
- The report also features the SWOT analysis with analyst views for XOLAIR in CSU.
Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.XOLAIR Analytical Perspective
In-depth XOLAIR Market Assessment
This report provides a detailed market assessment of XOLAIR for Chronic Spontaneous Urticaria (CSU) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.XOLAIR Clinical Assessment
The report provides the clinical trials information of XOLAIR for Chronic Spontaneous Urticaria (CSU) covering trial interventions, trial conditions, trial status, start and completion dates.Report Highlights
- In the coming years, the market scenario for Chronic Spontaneous Urticaria (CSU) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XOLAIR dominance.
- Other emerging products for CSU are expected to give tough market competition to XOLAIR and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XOLAIR in CSU.
- This in-depth analysis of the forecasted sales data of XOLAIR from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XOLAIR in CSU.
Key Questions Answered
- What is the product type, route of administration and mechanism of action of XOLAIR?
- What is the clinical trial status of the study related to XOLAIR in Chronic Spontaneous Urticaria (CSU) and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XOLAIR development?
- What are the key designations that have been granted to XOLAIR for CSU?
- What is the forecasted market scenario of XOLAIR for CSU?
- What are the forecasted sales of XOLAIR in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
- What are the other emerging products available and how are these giving competition to XOLAIR for CSU?
- Which are the late-stage emerging therapies under development for the treatment of CSU?
This product will be delivered within 2 business days.
Table of Contents
1. Report Introduction3. Competitive Landscape (Marketed Therapies)4. Competitive Landscape (Late-stage Emerging Therapies)6. SWOT Analysis7. Analysts’ Views9. Publisher Capabilities10. Disclaimer11. About the Publisher12. Report Purchase Options
2. XOLAIR Overview in Chronic Spontaneous Urticaria (CSU)
5. XOLAIR Market Assessment
8. Appendix
List of Tables
List of Figures
